Efficacy of Xpert MTB/RIF Ultra in diagnosing tuberculosis meningitis
A systematic review and meta-analysis

Yanqin Shen, Bachelor’s Degree, Guocan Yu, Bachelor’s Degree, Wuchen Zhao, Master’s Degree, Yazhen Lang, Bachelor’s Degree

Abstract
Background: This study aimed to assess whether Xpert MTB/RIF Ultra (Xpert Ultra) can effectively diagnose tuberculosis meningitis (TBM) and to simultaneously compare its effectiveness with Xpert in diagnosing TBM in the same population.

Methods: On August 12, 2020, Wanfang Database, China National Knowledge Infrastructure, Embase, Cochrane Library, and PubMed were searched for studies evaluating the diagnostic accuracy of Xpert Ultra for TBM. Then, we assessed the efficacy of Xpert Ultra against a composite reference standard and culture. If applicable, we also examined the diagnostic efficacy of Xpert in the same population. Heterogeneity was then explored by meta-regression, subgroup, and sensitivity analyses.

Results: Six studies containing 601 specimens reported the diagnostic efficacy of Xpert Ultra for TBM, with a composite reference standard. No study had compared the efficacy between Xpert Ultra and culture. The pooled sensitivity of Xpert Ultra was 64% (95% confidence interval [CI]: 45–80), and the I² value was 86% (95% CI: 76–96); its specificity for TBM was consistently 100%. In the same population, 5 studies compared the diagnostic efficacy between Xpert Ultra and Xpert for TBM. The pooled sensitivity of Xpert Ultra and Xpert was 68% (95% CI: 46–84; I²=87%) and 37% (95% CI: 25–50; I² = 72%), respectively. The studies were significantly heterogeneous in terms of sensitivity but not heterogeneous in specificity.

Conclusions: Xpert Ultra was more sensitive than Xpert, but both were specific (100%). Therefore, Xpert Ultra had an excellent diagnostic efficacy for TBM, and it could be the preferred initial test for TBM.

Abbreviations: AFB = acid-fast bacilli, CI = confidence interval, CRS = composite reference standard, CSF = cerebrospinal fluid, EPTB = extrapulmonary tuberculosis, FN = false negative, FP = false positive, MTB = Mycobacterium tuberculosis, NAAT = nucleic acid amplification tests, TBM = tuberculous meningitis, TN = true negative, TP = true positive.

Keywords: efficacy, meta-analysis, tuberculosis meningitis, Xpert, Xpert Ultra.

1. Introduction

Tuberculosis (TB) remains a serious global challenge to public health.[1] In 2018, TB was found in more than 10 million individuals, resulting in 1.5 million deaths[1]; thus, it becomes the leading cause of death among infectious diseases.[2] According to the presence or absence of lung involvement after Mycobacterium tuberculosis (MTB) infection, TB has 2 main categories: pulmonary tuberculosis and extrapulmonary tuberculosis (EPTB).[3] The most serious type of EPTB is tuberculosis meningitis (TBM); although its incidence is low, accounting for only 1% to 5% of new tuberculosis infections, it causes severe disability or death in nearly half of the infected individuals.[4] One of the main causes of these serious complications is the lack of early and effective diagnostic tools, leading to delayed diagnosis and consequently, missed treatment.[5] Therefore, early diagnosis is paramount in TBM management. Classical microbiological assays cannot achieve an early and rapid diagnosis.[6] The most widely used tool for TBM diagnosis is cerebrospinal fluid (CSF) acid-fast bacilli (AFB) smear with Ziehl–Neelsen staining, owing to its simplicity and user-friendliness. However, AFB is insensitive, especially when professional testers are unavailable.[7] Although MTB culture is more sensitive than AFB, the culture requires at least 2 weeks to produce the results; thus, early clinical applications are not possible.[8] Therefore, MTB culture is not effective for early diagnosis.[9] Hence, a rapid and effective test for TBM is urgently needed.

Meanwhile, nucleic acid amplification tests (NAATs) are gaining prominence in rapid TB diagnosis.[10] Xpert MTB/RIF (Xpert, Cepheid, Sunnyvale, CA, USA) is the most classical and
widely used NAAT.\(^1\)\(^1\) Xpert can rapidly diagnose TB; hence, it was recommended for the early diagnosis of pulmonary tuberculosis in 2010 and for some types of EPTB in 2013 by the World Health Organization.\(^1\)\(^2\) However, the test is still flawed, and its sensitivity remains low in EPTB (eg, TB meningitis and tuberculous pleurisy) with low bacterial content.\(^1\)\(^3\) For TB meningitis, although the World Health Organization recommends Xpert as the initial test, its sensitivity remains unsatisfactory.\(^1\)\(^4\) A negative Xpert result does not provide enough confidence to rule out TB.

To improve the diagnostic performance for paucibacillary TB, Cepheid developed Xpert MTB/RIF Ultra (Xpert Ultra), which is the next-generation Xpert; it shares the same equipment platform with Xpert with updating.\(^1\)\(^5\)\(^-\)\(^6\) Xpert Ultra adds 2 new MTB target genes (IS1081 and IS6110) and provides a larger capacity for DNA amplification reaction chamber.\(^1\)\(^6\) These improvements greatly enhance the effectiveness of Xpert Ultra in diagnosing TB.\(^1\)\(^6\)\(^-\)\(^7\) The diagnostic efficacy of Xpert Ultra is also beneficial for paucibacillary TB,\(^1\)\(^8\)\(^-\)\(^20\) However, the diagnostic efficacy of Xpert Ultra for TB meningitis in comparison with culture or a composite reference standard (CRS) remains controversial; 1 study showed that Xpert Ultra was more effective than Xpert\(^2\)\(^1\) but another study demonstrated that the efficacy of Xpert Ultra revealed no statistically significant improvement than that of Xpert.\(^2\)\(^2\) Hence, this study aimed to conduct a systematic review and meta-analysis to better assess the role of Xpert Ultra in TB meningitis diagnosis in comparison with the CRS and to simultaneously compare its effectiveness with Xpert when diagnosing TB in the same population.

2. Material and methods

2.1. Design and registration

We designed a systematic review and meta-analysis to assess the efficacy of Xpert Ultra in diagnosing TB meningitis. We registered the protocol on the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY, registration number: INPLASY202080045).\(^2\)\(^3\) The study results were reported in reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statements.\(^2\)\(^4\) Furthermore, ethical approval was waived for systematic review and meta-analysis.

2.2. Information sources

On August 12, 2020, Wanfang Database, China National Knowledge Infrastructure, Embase, Cochrane Library, and PubMed were searched for studies assessing the diagnostic accuracy of Xpert Ultra in diagnosing TB meningitis. The publication time period of articles was from the database creation to August 12, 2020. Relevant references cited in the review were also screened to find studies that potentially met the criteria.

2.3. Search strategy

YS and GY designed the search strategies for this study. Our search had no language or time limits. The search formula of PubMed is listed as follows:

\#1 “Tuberculosis, Meningeal”[Mesh] OR “Meningeal Tuberculosis” OR “Meningeal Tuberculosis” OR “Tuberculososes, Meningeal” OR “TB Meningitis” OR “TB Meningitides” OR “Tubercular Meningitis” OR “Meningitides, Tubercular” OR “Meningitis, Tubercular” OR “Tubercular Meningitides” OR “Meningitis, Tuberculous” OR “Meningitides, Tuberculous” OR “Tuberculous Meningitides” OR “Meningitis” OR “Tuberculosis Meningitis” OR “Meningitides, Tuberculous” OR “Tuberculous Meningitis” OR “Meningitis” OR “Tuberculosis” OR “Meningitides, Tuberculous” OR “Tuberculous” OR “Meningitis” OR “Tuberculosis” OR “Meningitides” OR “Tuberculous” OR “Meningitis” OR “Tuberculosis”. OR “Meningitides” OR “Tuberculous” OR “Meningitis” OR “Tuberculosis”.

2.4. Eligibility criteria

2.4.1. Type of study. Any type of study that had evaluated the accuracy of Xpert Ultra for TB meningitis.

2.4.2. Participants. TB meningitis participants diagnosed using Xpert Ultra without any limitations on age, gender, or nationality.

2.4.3. Index test. Xpert Ultra was considered as the index test.

2.4.4. Comparator test. A comparator test was optional. A study with satisfied participants, intervention, and outcomes can be enrolled even if it was a single-arm study.

2.4.5. Target conditions. Full-text original studies evaluating the Xpert Ultra assay in TB meningitis diagnosis, with clear reference standards and comprehensive data to extract or calculate true positive (TP), false positive (FP), false negative (FN), and true negative (TN) values, were considered eligible, thereby included in the study. However, studies published in languages other than English and Chinese, abstracts and conference reports without full text, case reports, and studies with <10 specimens did not meet the criteria; thus, they were excluded.

2.4.6. Outcomes. The main outcomes were the sensitivity and specificity of the Xpert Ultra system for TB meningitis. Sensitivity refers to the probability that the index test result will be positive in an infected case, the calculation formula is TP/(TP+FN)×100%. Specificity refers to the probability that the index test result will be negative in a non-infected case, the calculation formula is TN/(FP+TN)×100%.

2.4.7. Reference standards. Culture or a CRS was used as the reference standard. A CRS comprised clinical symptoms, imaging features, CSF biochemical analysis, MTB smears, culture, and effectiveness to anti-TB therapy.
2.5. Literature screening and selection

The collected works of literature were managed by the ENDNOTE X9.2 literature management software (Clarivate Corporation, Stanford, USA), where all search records were imported. In selecting eligible articles, YS and GY independently assessed all imported articles by reviewing their titles and abstracts and then the full text according to the inclusion criteria. Any dispute that occurred between the 2 researchers was discussed with another researcher (YL). First, we gave the controversial literature to a third researcher for independent evaluation, then the 3 researchers discussed and reported the reasons for inclusion or exclusion, respectively, and then the literature was included or excluded according to the inclusion and exclusion criteria after obtaining agreement.

2.6. Data extraction

For each included article, the following were extracted: first author’s name; publication year; country; TP, FP, FN, and TN values for the assay; research type; patient selection method; sample type; sample condition; decontamination method; and homogenization along with other parameters. If an article compared the diagnostic efficacy of the Xpert Ultra and Xpert in the same population, the relevant data of the Xpert were similarly extracted. The same 2 researchers individually extracted the aforementioned relevant data from each included article and then cross-checked them, with the disputed data being resolved by discussing with the third researcher.

2.7. Quality evaluation

The quality of the included literature was assessed by the same 2 researchers using a revised tool for the Quality Assessment of Diagnostic Accuracy Studies independently. Any disagreement between researchers was resolved via a discussion with the third researcher (YL). According to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Diagnostic Test Accuracy guideline, publication bias did not need to be assessed.

2.8. Data synthesis and statistical analysis

Initially, we determined the TP, FP, FN, and TN values for each study. Then, the pooled sensitivity and specificity with 95% confidence interval (CI) of the Xpert Ultra or Xpert for TBM diagnosis in comparison with the CRS were calculated using the bivariate random-effects models. The forest plots of the sensitivity and specificity for each study were generated using RevMan version 5.3 (Cochrane Collaboration, Oxford, United Kingdom). Meanwhile, heterogeneity between the studies was assessed using the $I^2$ statistics. A value of 0% indicated no heterogeneity, whereas a value >50% indicated substantial heterogeneity. Heterogeneity sources were explored by meta-regression, subgroup, and sensitivity analyses. Potential sources of heterogeneity included the patient selection method, sample condition, decontamination method, and homogenization. Meta-analyses and meta-regression analyses were conducted using Stata version 15.0 (Stata Corp., College Station, TX, the USA) and midas. At least 4 studies were required for meta-analysis to obtain the combined effect values for each preset parameter using Stata.

3. Results

3.1. Characteristics of the studies

By searching the relevant databases using our designed search strategies, we acquired 153 candidate articles. Ultimately, we found 6 articles that met the inclusion criteria for the final quantitative analysis (Fig. 1). The study type of all 6 included articles was a prospective study. The kappa value of agreement between the 2 researchers at the literature screening and data extraction stages was 0.736 (95% CI: 0.489–0.983). All studies were conducted in developing countries with TB epidemic, with English as the language of publication. In addition, CSF is the selected specimen type for all articles. All studies used CRS as the reference standard, and no studies used culture as the reference standard. Five articles simultaneously compared the diagnostic efficacy of Xpert Ultra and Xpert in TBM against CRS in the same population. The range of study specimen volume for Xpert Ultra was 21 to 204, with a median specimen volume of 93.5 and a total specimen volume of 601. For Xpert, the range of study specimen volume was 21 to 166, with a median specimen volume of 102 and a total specimen volume of 478. Table 1 lists the characteristics of the included studies. However, 2 articles were excluded because 1 article only reported sensitivity and the other 1 analyzed the same data as 1 of the included articles. We also excluded 2 articles that did not separately report data related to Xpert Ultra for TBM diagnosis.

3.2. Study quality

The results of the overall methodological quality assessment of the included studies are displayed in Figure 2, with the CRS as the reference standard. The risk of bias emerged primarily from patient selection and the reference standard; nonetheless, its flow and timing from the index test were relatively low.

3.3. Diagnostic efficacy of Xpert Ultra and Xpert for TBM

Six studies containing 601 specimens reported the efficacy of Xpert Ultra, with a CRS, in diagnosing TBM. The sensitivity of Xpert Ultra ranged from 44% (95% CI: 29–60) to 95% (95% CI: 77–100), whereas its pooled sensitivity in diagnosing TBM was 64% (95% CI: 45–80), with the $I^2$ value of 86% (95% CI: 76–96); its specificity for TBM was consistent (all 100%) (Fig. 3). The studies were significantly heterogeneous in terms of sensitivity but not heterogeneous in specificity.

Meanwhile, 5 studies containing 478 specimens reported the diagnostic efficacy of Xpert, with a CRS, for TBM. The specificity of Xpert ranged from 19% (95% CI: 8–33) to 56% (95% CI: 40–70), whereas its pooled sensitivity in diagnosing TBM was 37% (95% CI: 25–50), with the $I^2$ value of 72% (95% CI: 46–98). The specificity of the Xpert for TBM was also consistent (all 100%) (Fig. 3). The studies were significantly heterogeneous in terms of sensitivity.

For all studies, Xpert Ultra had a higher pooled sensitivity than Xpert, but the specificity of both was consistent. For the same population, 5 studies compared the efficacy of Xpert Ultra and Xpert in diagnosing TBM. The pooled sensitivity of Xpert Ultra and Xpert was 68% (95% CI: 46–84; $I^2 = 87\%$) and 37% (95% CI: 25–50; $I^2 = 72\%$), respectively (Fig. 4). In each study, Xpert Ultra had higher sensitivity and pooled sensitivity than Xpert.
The heterogeneity between studies in terms of sensitivity was determined by meta-regression, subgroup, and sensitivity analyses. The patient selection method, sample condition, decontamination method, and homogenization method used in the assay of the predefined subgroups were assessed by meta-regression and subgroup analyses. Meta-regression analysis demonstrated that the patient selection method, sample condition, decontamination method, and homogenization method did not affect the sensitivity of Xpert Ultra and Xpert for TBM diagnosis in comparison with the CRS (meta-regression $P > .05$). In the subgroup analyses performed on the subgroups of the consecutive patient selection method, decontamination without $N$-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH), and mechanical homogenization method of Xpert Ultra, the

![Figure 1](image.png)

**Figure 1.** Flow chart of literature retrieval. In total, 3, 96, 10, 10, and 34 articles were found in Wanfang Database, China National Knowledge Infrastructure, Embase, Cochrane Library, and PubMed, respectively.

**Table 1.** Characteristics of the included studies.

| Test   | Author          | Year | County  | Sample type | Reference | Research type | N   | TP | FP | FN | TN  | Decontaminate method | Sample condition | Homogenisation | patient selection method |
|--------|-----------------|------|---------|-------------|-----------|---------------|-----|----|----|----|-----|----------------------|------------------|----------------|------------------------|
| Xpert  | Bahr et al      | 2018 | Uganda | CSF         | CRS       | Prospective   | 129 | 21 |  0 |  1 | 107 | No                   | Frozen           | Mechanical     | Consecutive            |
|        | Wang et al      | 2019 | China  | CSF         | CRS       | Prospective   | 60  | 19 |  0 | 24 | 17  | NALC-NaOH            | Frozen           | Mechanical     | Consecutive            |
|        | Zhang et al     | 2019 | China  | CSF         | CRS       | Prospective   | 21  | 10 |  0 |  5 |  6  | NALC-NaOH            | Fresh            | Mechanical     | Convenience            |
|        | Cresswell et al | 2020 | Uganda | CSF         | CRS       | Prospective   | 204 | 39 |  0 | 12 | 153 | No                   | Fresh            | No             | Convenience            |
|        | Donovan et al   | 2020 | Vietnam| CSF         | CRS       | Prospective   | 103 | 25 |  0 | 28 | 50  | No                   | Fresh            | Mechanical     | Convenience            |
|        | Shao et al      | 2020 | China  | CSF         | CRS       | Prospective   | 84  | 28 |  0 | 32 | 24  | No                   | Frozen           | No             | Consecutive            |
| Xpert  | Bahr et al      | 2018 | Uganda | CSF         | CRS       | Prospective   | 129 | 10 |  0 | 12 | 107 | No                   | Frozen           | Mechanical     | Consecutive            |
|        | Wang et al      | 2019 | China  | CSF         | CRS       | Prospective   | 60  |  8 |  0 | 35 | 17  | NALC-NaOH            | Frozen           | Mechanical     | Consecutive            |
|        | Zhang et al     | 2019 | China  | CSF         | CRS       | Prospective   | 21  |  4 |  0 | 11 |  6  | NALC-NaOH            | Fresh            | Mechanical     | Convenience            |
|        | Cresswell et al | 2020 | Uganda | CSF         | CRS       | Prospective   | 166 | 25 |  0 | 20 | 121 | No                   | Fresh            | No             | Consecutive            |
|        | Donovan et al   | 2020 | Vietnam| CSF         | CRS       | Prospective   | 102 | 21 |  0 | 32 | 49  | No                   | Fresh            | Mechanical     | Convenience            |

CRS = composite reference standard, CSF = cerebrospinal fluid, FN = false negative, FP = false positive, TN = true negative, TP = true positive.
heterogeneity between studies in the subgroups remained highly significant ($I^2 > 50\%$). For the Xpert, the heterogeneity also remained highly significant ($I^2 > 50\%$) according to the subgroup analyses that were performed on the subgroup of mechanical homogenization method. However, the studies included in other subgroups of Xpert were limited; thus, subgroup analysis could not be conducted. In sensitivity analyses, a particular study was either included or excluded to reanalyze whether the conclusions had changed. Unfortunately, sensitivity analysis did not identify studies that resulted in significant heterogeneity.

4. Discussion
Similar to other paucibacillary EPTB, the MTB content of the test specimen was low, making the early diagnosis of TBM extremely difficult.[36] Delays in early diagnosis allow for treatment deficits, preventing patients to receive optimal treatments and leading to serious consequences, such as severe disability and death. As a result, the patient’s prognosis worsens, and the burden on the patient’s family increases.[22] In patients with suspected TBM, a lumbar puncture to obtain a CSF sample for correlation testing is the most common and critical step. However, the MTB content in CSF is extremely low, and the probability of obtaining a positive result by AFB and culture is also very low[37]; therefore, diagnosing TBM using these 2 methods alone still does not meet the clinical needs.[37] In the studies included in this meta-analysis, no study had compared the sensitivity and specificity between Xpert Ultra and culture; thus, the current study used CRS as the reference standard for correlation analysis. However, larger clinical studies are required to confirm the relevant diagnostic efficacy of Xpert Ultra in comparison with that of culture.

Figure 2. Methodological quality graphs of risk of bias and applicability concerns, presented as percentages across the included studies against the composite reference standard. (A) Xpert Ultra. (B) Xpert.

Figure 3. Forest plot for the sensitivity and specificity of Xpert Ultra and Xpert for the diagnosis of tuberculosis meningitis diagnosis against a composite reference standard.
Aside from AFB and culture, other valid tests have also been explored for TBM diagnosis. Owing to molecular biology advancement, rapid microbiological testing was made possible, with NAAT as the crucial step. Xpert is the leading NAAT in TB diagnostics and is widely used. This test has led to a significant increase in the diagnostic efficacy of TB because it shortens the diagnosis time and allows a considerably earlier therapeutic window, thereby beneficial for TB control. However, Xpert still seems impractical for paucibacillary EPTB such as TBM. Xpert’s diagnostic performance in TBM remains unsatisfactory. Therefore, more efficient detection methods are still being developed. Based on the Xpert, the second-generation Xpert Ultra was developed by Cepheid. According to numerous reported improvements, the Xpert Ultra is considerably more sensitive than the Xpert. However, the diagnostic performance of the Xpert Ultra for TBM remains unclear. Most of the studies agreed that the Xpert Ultra is more sensitive than the Xpert statistically, but another study reported otherwise. Although a meta-analysis mentioned the role of Xpert Ultra in TBM, the study included only 2 papers on TBM, an extremely limited number, and our study included more studies, and the results might be more informative. To the best of our knowledge, no independent systematic review and meta-analysis on the efficacy of Xpert Ultra in TBM diagnosis are available; hence, we conducted the present study.

Six studies using CRS as the gold standard were included in this study; they demonstrated that Xpert Ultra had a pooled sensitivity of 64% and a specificity of 100% for TB diagnosis, indicating that Xpert Ultra has good diagnostic efficacy for TB. The sensitivity results across independent studies were strikingly different, and a substantial level of heterogeneity was observed. Moreover, 5 studies compared the efficacy between Xpert Ultra and Xpert for TBM diagnosis in the same population. The pooled sensitivity of Xpert Ultra and Xpert was 68% and 37%, respectively, and the specificity of both tests was tremendously high (100%). In the same population, the sensitivity of Xpert Ultra was significantly better than that of Xpert. The sensitivity of Xpert in this population was low, possibly related to the low number of specimens included in the study. A recent meta-analysis on Xpert for TBM diagnosis showed that the Xpert had a pooled sensitivity of 63% and a pooled specificity of 98.1%. Although the Xpert sensitivity of that study was higher than ours, it was still lower than the sensitivity of Xpert Ultra in this study. Meanwhile, the present study did not compare the sensitivity and specificity between the 2 tests and culture examination. As a composite standard with multiple factors, CRS might lead to sensitivity decrement and specificity increment. Therefore, for TBM confirmed by a positive CSF culture, the sensitivity of Xpert Ultra should be higher than that observed in the current study.

Moreover, we observed significant heterogeneity in the sensitivity of Xpert Ultra and Xpert. The patient selection method, sample condition, decontamination method, and homogenization method were different among the studies. The sources of heterogeneity were explored in these terms. However, according to the meta-regression and subgroup analyses, these factors did not affect the sensitivity. Similarly, the sensitivity analysis did not reveal particularly heterogeneous articles. In addition, CRS might be different in each independent study (eg, some studies had not included treatment response), which itself might be a source of heterogeneity.

This meta-analysis had several limitations. Some studies might be missed during literature screening, although we had tried to expand the search the best that we could. In addition, some studies did not report TBM data separately; hence, the final results might be biased. The CRS might also differ across individual studies. The sensitivity between the studies was clearly heterogeneous; therefore, the pooled estimates of sensitivity must be treated prudently.

5. Conclusions
This was the first independent systematic review and meta-analysis on the efficacy of Xpert Ultra in TBM diagnosis. The pooled sensitivity and specificity of Xpert Ultra for TBM diagnosis were 64% and 100%, respectively. Xpert Ultra was more sensitive than Xpert, and both were identical in terms of specificity (100%). Therefore, Xpert Ultra is highly effective in diagnosing TBM, and it could be the preferred initial test for TBM.

Acknowledgments
We thank the patients and their families who were included in this study, and our colleagues in the department.

Author contributions
Data curation: Yanqin Shen, Guocan Yu, Yazhen Lang.
References

[1] World Health Organization. Global Tuberculosis Report 2019. 2019.
[2] Cresswell FV, Ellis J, Kagimu E, et al. Standardized urine-based tuberculosis (TB) screening with TB-lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan adults with advanced human immunodeficiency virus disease and suspected meningitis. Open Forum Infect Dis 2020;7:ofaa100.
[3] Sunnetcigola A, Sunnetcigol M, Binici I, Baran AI, Karahocagil MK, Saydan MR. Comparative analysis of pulmonary and extra-pulmonary tuberculosis of 411 cases. Ann Clin Microbiol Antimicrob 2015;14:434.
[4] Thao LTP, Heemskerk AD, Geskus RB, et al. Prognostic models for 9-month mortality in tuberculosis meningitis. Clin Infect Dis 2018;66: 523–52.
[5] Sheu JJ, Yuan RY, Yang CC. Predictors for outcome and treatment delay in patients with tuberculosis meningitis. Am J Med Sci 2009;338:134–9.
[6] Thwaites GE. Advances in the diagnosis and treatment of tuberculosis meningitis. Curr Opin Neurol 2013;26:295–300.
[7] Heemskerk AD, Donovan J, Thu DDA, et al. Improving the microbiological diagnosis of tuberculosis meningitis: a prospective, international, multicentre comparison of conventional and modified Ziehl-Neelsen stain, GeneXpert, and culture of cerebrospinal fluid. J Infect 2018;77:509–15.
[8] Wilkinson RJ, Rohlikv M, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol 2017;13:581–98.
[9] Wang YY, Xie BD. Progress on diagnosis of tuberculosis meningitis. Methods Mol Biol 2018;1754:375–86.
[10] Chitnis AS, Davis JL, Schecter GF, Barry PM, Flood JM. Review of WHO Guidelines Approved by the Guidelines Review Committee. Autogenous Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF assay for the Diagnosis of Meningitis and Xpert TB in Adults and Children: Policy Update. Geneva: World Health Organization; 2013.
[11] Kohli M, Schiller I, Dendukuri N, et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev 2018;8:CD012768.
[12] WHO Guidelines Approved by the Guidelines Review Committee. Automated Real-Time Nucelic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF assay for the Diagnosis of Meningitis and Extrapulmonary TB in Adults and Children: Policy Update. Geneva: World Health Organization; 2013.
[13] Huo ZY, Peng L. Is Xpert MTB/RIF appropriate for diagnosing tuberculous pleurisy with pleural fluid samples? A systematic review. BMC Infect Dis 2018;18:284.
[14] Bahr NC, Marais S, Cawas M, et al. GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last. Clin Infect Dis 2016;62:1133–5.
[15] Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clin Microbiol Infect 2019;25:1370–6.
[16] Chakravorty S, Simmons AM, Rowneke M, et al. The new Xpert MTB/RIF Ultra: improving detection of Mycobacterium tuberculosis and resistance to rifampicin in an assay suitable for point-of-care testing. mBio 2017;29:8.
[17] Horne DJ, Kohli M, Zifodya JS, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2019;6:CD009593.
[18] Bisognin F, Lombardi G, Lombardo D, Re MC, Dal Monte P. Improvement of Mycobacterium tuberculosis detection by Xpert MTB/RIF Ultra: a head-to-head comparison on Xpert-negative samples. PLoS One 2018;13:e0201934.
[19] Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 2018;18:76–84.
[20] Wang, Wang, Yang X, et al. Accuracy of Xpert MTB/RIF Ultra for the diagnosis of pleural TB in a multicenter cohort study. Chest 2019;157:268–75.
[21] Cresswell FV, Tugume L, Bahr NC, et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infect Dis 2020;20:308–17.
[22] Donovan J, Thu DDA, Phu NH, et al. Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculosis meningitis: a prospective, randomised, diagnostic accuracy study. Lancet Infect Dis 2020;20:299–307.
[23] Shen Y, Yu G, Zhao W, Lang LG. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis: a protocol of systematic review and meta-analysis. Inplasy Protocol 2020;doi: 10.37766/inplasy2020.8.0045.
[24] Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Statement. PLoS Med 2009;6:e1000097.
[25] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
[26] McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA 2018;319:388–96.
[27] Yu G, Zhong F, Ye B, Xu X, Chen D, Shen Y. Diagnostic accuracy of the Xpert MTB/RIF assay for lymph node tuberculosis: a systematic review and meta-analysis. Biomed Res Int 2019;2019:4878240.
[28] Bahr NC, Nuwagira E, Evans EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis 2018;18:68–75.
[29] Shao L, Qiu C, Zheng L, et al. Comparison of diagnostic accuracy of the GeneXpert Ultra and cell-free nucleic acid assay for tuberculous meningitis: a multicentre prospective study. Int J Infect Dis 2020;98:441–6.
[30] Wang G, Wang S, Jiang G, et al. Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: a prospective cohort study. J Infect 2019;78:311–6.
[31] Zhang P, Zheng J, Fu L, et al. Value of Xpert MTB/RIF Ultra in the diagnosis of tuberculous meningitis. J Tuberc Lung Health 2019;8:42–7. Chinese.
[32] Chin JH, Musubire AK, Morgan N, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis in cerebrospinal fluid. J Clin Microbiol 2019;57.
[33] Wang S. Diagnostic Value of Xpert MTB/RIF Ultra in Smear Negative Pulmonary Tuberculosis, Tuberculosis Pleurisy and Tuberculosis Menigitis. 2019:Beijing Tuberculosis Chest Cancer Institute, Chinese.
[34] Menchini M, Lari N, Lupetti A, Rindi L. Evaluation of Xpert MTB/RIF Ultra assay for rapid diagnosis of pulmonary and extra-pulmonary tuberculosis in an Italian center. Eur J Clin Microbiol Infect Dis 2020;39:1597–600.
[35] Wu X, Tan G, Gao R, et al. Assessment of the Xpert MTB/RIF Ultra assay on rapid diagnosis of extrapulmonary tuberculosis. Int J Infect Dis 2019;81:91–6.
[36] Arshad A, Dayal S, Gadhe R, et al. Analysis of tuberculosis meningitis pathogenesis, diagnosis, and treatment. J Clin Med 2020;9.
[37] Bahr NC, Meintjes G, Boulware DR. Inadequate diagnostics: the case to move beyond the bacilli for detection of meningitis due to Mycobacterium tuberculosis. J Med Microbiol 2019;68:755–60.
[38] Jiang J, Yang J, Shi Y, et al. Head-to-head comparison of the diagnostic accuracy of Xpert MTB/RIF and Xpert MTB/RIF Ultra for tuberculosis meningitis: a meta-analysis. Infect Dis (Lond) 2020;1–13.
[39] Chen YZ, Sun LC, Wen YH, et al. Pooled analysis of the Xpert MTB/RIF assay for diagnosing tuberculous meningitis. Biosci Rep 2020;31:40.